Physician profile
Carol Vance
NPI 1417012022
$484.30
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $161 · 2021: $165.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $230.88 | 2019-2021 | |
| Greenwich Biosciences, INC. | $101.43 | 2019-2021 | |
| Eisai INC. | $81.46 | 2021 | |
| Neurelis, INC. | $25.82 | 2020 | |
| Livanova USA, INC. | $25.09 | 2019-2021 | |
| Zogenix INC. | $19.62 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.